FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2621467536> ?p ?o ?g. }

• W2621467536 endingPage "1032" @default.
• W2621467536 startingPage "1024" @default.
• W2621467536 abstract "Secukinumab is a fully human antibody that neutralizes interleukin-17A. It has significant efficacy and a favourable safety profile in moderate-to-severe plaque psoriasis and psoriatic arthritis.To compare secukinumab with fumaric acid esters (FAEs) in a randomized controlled trial.In this 24-week, randomized, open-label, multicentre study with blinded assessment, patients with moderate-to-severe plaque psoriasis, naive to systemic treatments, were randomized to receive secukinumab 300 mg subcutaneously or oral FAEs. The primary end point was ≥ 75% improvement from baseline Psoriasis Area and Severity Index score (PASI 75 response) at week 24, and missing patients were considered responders if they were responders at the time of dropout.In total 202 patients were randomized and 200 were treated with at least one dose. Outcomes at week 24 were available for 147 and imputed for 53 patients. Discontinuations were mostly due to adverse events, and occurred more frequently in the FAE group (1·9% vs. 40·0%). At week 24, significantly more patients receiving secukinumab compared with FAEs achieved PASI 75 response (89·5% vs. 33·7%, P < 0·001), PASI 90 response (75·2% vs. 18·9%, P < 0·001) and Dermatology Life Quality Index 0 or 1 response (71·4% vs. 25·3%, P < 0·001).Secukinumab demonstrated superior efficacy to FAEs in patients with psoriasis over a 24-week period." @default.
• W2621467536 created "2017-06-15" @default.
• W2621467536 creator A5000572878 @default.
• W2621467536 creator A5006740586 @default.
• W2621467536 creator A5008588165 @default.
• W2621467536 creator A5013763025 @default.
• W2621467536 creator A5027225401 @default.
• W2621467536 creator A5027479980 @default.
• W2621467536 creator A5048237079 @default.
• W2621467536 creator A5048939519 @default.
• W2621467536 creator A5085831636 @default.
• W2621467536 date "2017-09-12" @default.
• W2621467536 modified "2023-10-12" @default.
• W2621467536 title "Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial" @default.
• W2621467536 cites W1508752722 @default.
• W2621467536 cites W1935617463 @default.
• W2621467536 cites W1963547816 @default.
• W2621467536 cites W1969546360 @default.
• W2621467536 cites W1973354423 @default.
• W2621467536 cites W2022093543 @default.
• W2621467536 cites W2026277530 @default.
• W2621467536 cites W2080237150 @default.
• W2621467536 cites W2097170399 @default.
• W2621467536 cites W2120422600 @default.
• W2621467536 cites W2336762206 @default.
• W2621467536 cites W2359919307 @default.
• W2621467536 cites W2419603827 @default.
• W2621467536 cites W2510028480 @default.
• W2621467536 cites W4250753642 @default.
• W2621467536 doi "https://doi.org/10.1111/bjd.15707" @default.
• W2621467536 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28580646" @default.
• W2621467536 hasPublicationYear "2017" @default.
• W2621467536 type Work @default.
• W2621467536 sameAs 2621467536 @default.
• W2621467536 citedByCount "46" @default.
• W2621467536 countsByYear W26214675362017 @default.
• W2621467536 countsByYear W26214675362018 @default.
• W2621467536 countsByYear W26214675362019 @default.
• W2621467536 countsByYear W26214675362020 @default.
• W2621467536 countsByYear W26214675362021 @default.
• W2621467536 countsByYear W26214675362022 @default.
• W2621467536 countsByYear W26214675362023 @default.
• W2621467536 crossrefType "journal-article" @default.
• W2621467536 hasAuthorship W2621467536A5000572878 @default.
• W2621467536 hasAuthorship W2621467536A5006740586 @default.
• W2621467536 hasAuthorship W2621467536A5008588165 @default.
• W2621467536 hasAuthorship W2621467536A5013763025 @default.
• W2621467536 hasAuthorship W2621467536A5027225401 @default.
• W2621467536 hasAuthorship W2621467536A5027479980 @default.
• W2621467536 hasAuthorship W2621467536A5048237079 @default.
• W2621467536 hasAuthorship W2621467536A5048939519 @default.
• W2621467536 hasAuthorship W2621467536A5085831636 @default.
• W2621467536 hasBestOaLocation W26214675361 @default.
• W2621467536 hasConcept C126322002 @default.
• W2621467536 hasConcept C16005928 @default.
• W2621467536 hasConcept C168563851 @default.
• W2621467536 hasConcept C197934379 @default.
• W2621467536 hasConcept C203092338 @default.
• W2621467536 hasConcept C2776173921 @default.
• W2621467536 hasConcept C2776260265 @default.
• W2621467536 hasConcept C2777011040 @default.
• W2621467536 hasConcept C2778690821 @default.
• W2621467536 hasConcept C2779786854 @default.
• W2621467536 hasConcept C2780564577 @default.
• W2621467536 hasConcept C3020604521 @default.
• W2621467536 hasConcept C47348012 @default.
• W2621467536 hasConcept C71924100 @default.
• W2621467536 hasConcept C90924648 @default.
• W2621467536 hasConceptScore W2621467536C126322002 @default.
• W2621467536 hasConceptScore W2621467536C16005928 @default.
• W2621467536 hasConceptScore W2621467536C168563851 @default.
• W2621467536 hasConceptScore W2621467536C197934379 @default.
• W2621467536 hasConceptScore W2621467536C203092338 @default.
• W2621467536 hasConceptScore W2621467536C2776173921 @default.
• W2621467536 hasConceptScore W2621467536C2776260265 @default.
• W2621467536 hasConceptScore W2621467536C2777011040 @default.
• W2621467536 hasConceptScore W2621467536C2778690821 @default.
• W2621467536 hasConceptScore W2621467536C2779786854 @default.
• W2621467536 hasConceptScore W2621467536C2780564577 @default.
• W2621467536 hasConceptScore W2621467536C3020604521 @default.
• W2621467536 hasConceptScore W2621467536C47348012 @default.
• W2621467536 hasConceptScore W2621467536C71924100 @default.
• W2621467536 hasConceptScore W2621467536C90924648 @default.
• W2621467536 hasFunder F4320332736 @default.
• W2621467536 hasIssue "4" @default.
• W2621467536 hasLocation W26214675361 @default.
• W2621467536 hasLocation W26214675362 @default.
• W2621467536 hasOpenAccess W2621467536 @default.
• W2621467536 hasPrimaryLocation W26214675361 @default.
• W2621467536 hasRelatedWork W2285826736 @default.
• W2621467536 hasRelatedWork W2565883611 @default.
• W2621467536 hasRelatedWork W2895404113 @default.
• W2621467536 hasRelatedWork W2922470754 @default.
• W2621467536 hasRelatedWork W2954778191 @default.
• W2621467536 hasRelatedWork W3005956004 @default.
• W2621467536 hasRelatedWork W3016311117 @default.
• W2621467536 hasRelatedWork W3190411311 @default.
• W2621467536 hasRelatedWork W4234288250 @default.

• next